ES2189404T3 - 1,3,4-tiadiazoles utiles para el tratamiento de infecciones por cmv. - Google Patents

1,3,4-tiadiazoles utiles para el tratamiento de infecciones por cmv.

Info

Publication number
ES2189404T3
ES2189404T3 ES99912221T ES99912221T ES2189404T3 ES 2189404 T3 ES2189404 T3 ES 2189404T3 ES 99912221 T ES99912221 T ES 99912221T ES 99912221 T ES99912221 T ES 99912221T ES 2189404 T3 ES2189404 T3 ES 2189404T3
Authority
ES
Spain
Prior art keywords
cmv
useful
tiadiazols
infections
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99912221T
Other languages
English (en)
Inventor
Steven R Turner
Suvit Thaisrivongs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2189404T3 publication Critical patent/ES2189404T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Un compuesto para uso en terapia como agente antivírico, compuesto que tiene la fórmula I**(Fórmula)** o una de sus sales farmacéuticamente aceptables, en la que Y es (a) -NHR1, o (b) **(Fórmula)** X es (a) -O-, (b) -S(=O)h-, (c) -CH2-, o (d) -NR2-, R1 es (a) alquilo C1-18, (b) -(CH2)i cicloalquilo C3-7, (b) -(CH2)i cicloalquilo C3-7 (c) -bicicloalquilo (CH2)i, (d) -(CH2)j- M (e) -(CH2)j- W, (f) -(CH)k arilo, pudiendo estar sustituido el grupo arilo con 1 a 3 R3, (g) -(CH2)k- het, pudiendo estar sustituido het con 1 a 3 R3, (h) -(CH2)k- Q, pudiendo estar sustituido Q con 1 a 3 R3, o (i) H; R2 es (a) H, (b) alquilo C1-4, (c) -C(=O) alquilo C1-4, (d) -S(=O= alquilo C1-4, (e) CO2 alquilo C1-4, o (f) -CO2CH2 fenilo; R3 es (a) halo, (b) alquilo C1-4, (c) alcoxi C1-4, (d) bencilo, (e) -CN, (f) -SO2F, (g) -SO2NH2, (h) -CF3, (i) -NO2, (j) -OCH2O(k) -CO2 (alquilo C1-4), (l) -C(=O) (alquilo C1-4), (m) -C(=O)NH2, (n) -NHCO2 (alquilo C1-4), o (o) -C(=O)-O-C(=O)-; M es (a) -CN, (b) -halo, (c) -CO2 alquilo C1_4, (d) -CH (fenilo)2, (e) **(Fórmula)** f) **(Fórmula)** W es (a) -OR4, (b) -SR4, (c) -NHR5 o (d) -NR6R7; R4 es (a) alquilo C1-4, (b) cicloalquilo C3-7, o (c) arilo, R5 es (a) alquilo C1-4), (b) cicloalquilo C3-7, (c) arilo, o (d) -C(=O) alquilo C1-4, R6 y R7 son, independientemente (a) alquilo C1-4, o (b) R6 y R7 junto con nitrógeno forman un resto heterocíclico saturado de 4 a 6 miembros que tiene 1 o 2 átomos seleccionados entre el grupo constituido por oxígeno, nitrógeno y azufre; Rx es (a) alquilo C1-18, (b) alquenilo C2-18, (c) alquinilo C2-18, (d) alquilo C2-6 sustituido con 1-3 halos, alcoxi C1-3, -OH, -SH o -CO2H, (e) alquenilo C2-6 sustituido con arilo, pudiendo estar a su vez arilo sustituido con de 1 a 3 R3, (f) -(CH2) arilo, pudiendo estar arilo sustituido con de 1 a 3 R3, (g) -(CH2)j-Q, pudiendo estar sustituido het con 1 a 3 R3, (h) -(CH2)j-U, pudiendo estar sustituido U con 1 a 3 R3, arilo es fenilo o naftilo; het es un resto heterocíclico insaturado de 5 a 10 miembrosque tiene de 1 a 3 átomos seleccionados entre el grupo constituido por oxígeno, nitrógeno y azufre; U es un resto heterocíclico insaturado de 5 o 9 miembros que tiene de 1 a 3 átomos seleccionados entre el grupo constituido por oxígeno, nitrógeno y azufre; Q es un resto heterocíclico insaturado de 5 o 6 miembros que tiene 1 ó 2 átomos seleccionados entre el grupo constituido por oxígeno, nitrógeno y azufre, pudiendo estar a su vez el átomo de nitrógeno sustituido con alquilo C1-4, fenilo, bencilo, -C(=O) alquilo C1-4 o -CO2 alquilo C1-4; h es 0, 1 o 2; i es 0, 1, 2, 3 o 4; j es 2, 3 o 4; y k es 0, 1, 2, 3, 4, 5 o 6.
ES99912221T 1998-03-19 1999-03-16 1,3,4-tiadiazoles utiles para el tratamiento de infecciones por cmv. Expired - Lifetime ES2189404T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7852898P 1998-03-19 1998-03-19

Publications (1)

Publication Number Publication Date
ES2189404T3 true ES2189404T3 (es) 2003-07-01

Family

ID=22144610

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99912221T Expired - Lifetime ES2189404T3 (es) 1998-03-19 1999-03-16 1,3,4-tiadiazoles utiles para el tratamiento de infecciones por cmv.

Country Status (11)

Country Link
US (1) US6150385A (es)
EP (1) EP1064273B1 (es)
JP (1) JP2002506858A (es)
AT (1) ATE229945T1 (es)
AU (1) AU743489B2 (es)
CA (1) CA2320167A1 (es)
DE (1) DE69904576T2 (es)
DK (1) DK1064273T3 (es)
ES (1) ES2189404T3 (es)
NZ (1) NZ507032A (es)
WO (1) WO1999047507A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500817B1 (en) 1999-03-08 2002-12-31 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
MXPA04005427A (es) * 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2289510A1 (en) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP2316458A1 (en) * 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
US8101618B2 (en) * 2005-04-06 2012-01-24 Msd K.K. 1,4-substituted piperazine derivatives
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
CA2711678A1 (en) * 2008-01-09 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
FR2945289A1 (fr) 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
EP2568809A4 (en) 2010-05-12 2013-11-06 Univ Vanderbilt HETEROCYCLIC ALLOSTERE SULFON MGLUR4 POTENTIATORS, COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS
RU2448961C1 (ru) * 2011-02-03 2012-04-27 Открытое акционерное общество "Всероссийский научный центр по безопасности биологически активных веществ" (ОАО "ВНЦ БАВ") Фармацевтическая композиция, обладающая противовоспалительной, бронхолитической, противотуберкулезной активностями
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
WO2014070976A1 (en) * 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
HUE035739T2 (en) 2013-01-14 2018-05-28 Molecular Insight Pharm Inc Triazine-based radiopharmaceuticals and radiological imaging agents
PH12018501979B1 (en) 2016-04-06 2023-05-05 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
PL3692039T3 (pl) 2017-10-05 2023-04-17 Innovative Molecules Gmbh Enancjomery podstawionych tiazoli jako związki przeciwwirusowe
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
CN114667285B (zh) 2019-09-26 2025-08-08 诺华股份有限公司 抗病毒吡唑并吡啶酮化合物
CN117695281B (zh) * 2023-12-26 2024-06-21 广州医科大学 四氢喹啉酮-酰胺-噻唑类化合物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8148047A0 (it) * 1981-03-18 1981-03-18 Manetti & Roberts Italo Brit Composti organici derivati da 2-ami no-5-(o-solfamidofenil)-1,3,4-tiadiazolo loro applicazione terapeutica e procedimento per la loro preparazione
ES2019294B3 (es) * 1985-12-16 1991-06-16 Lilly Co Eli Agentes antiviricos de tialiazol.
AU3886493A (en) * 1992-04-22 1993-11-18 Karin Elisabeth Peuschel Immuno-activating and hence anti-viral effect of 4-{3-(subst.-amino)-2-hydroxypropoxy}-1,2,5-thiadiazole compounds
JPH07149748A (ja) * 1993-09-30 1995-06-13 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体及びその製造法
JPH07188017A (ja) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
US5948916A (en) * 1994-09-22 1999-09-07 Rational Drug Design Laboratories Arylthiadiazole derivative and antiviral agent containing the same

Also Published As

Publication number Publication date
US6150385A (en) 2000-11-21
WO1999047507A2 (en) 1999-09-23
AU743489B2 (en) 2002-01-24
NZ507032A (en) 2003-06-30
DK1064273T3 (da) 2003-03-31
AU3063999A (en) 1999-10-11
DE69904576T2 (de) 2003-07-10
CA2320167A1 (en) 1999-09-23
EP1064273B1 (en) 2002-12-18
WO1999047507A3 (en) 1999-12-09
ATE229945T1 (de) 2003-01-15
EP1064273A2 (en) 2001-01-03
JP2002506858A (ja) 2002-03-05
DE69904576D1 (de) 2003-01-30

Similar Documents

Publication Publication Date Title
DK1064273T3 (da) 1,3,4-Thiadiazoler, som er nyttige til behandling af CMV-infektioner
BR9814323A (pt) 4-hidroxiquinolina-3-carboxamidas e hidrazidas como agentes antiviróticos
PT1066269E (pt) Derivados de 1,3,5-triazina trissubstrituidos para o tratamento de infeccoes por hiv
DE69909756D1 (de) Antivirale pyrimidinderivate
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
BR9914221B1 (pt) Derivados de glicopeptídeos e composições farmacêuticas contendo os mesmos
TR200101906T2 (tr) Antiviral ajanlar olarak kuinolinkarboksamitler
ES2139195T3 (es) Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
ATE231839T1 (de) Polyaromatische antivirale zusammensetzungen
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
MXPA03011906A (es) Derivados de imidazo' 1,2-a-piridina para la profilaxis y el tratamiento de infecciones virales por herpes.
ATE231149T1 (de) (1,8)-naphthyridinderivate derivate mit antiviraler wirkung
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
ES2184705T3 (es) 4-oxo-4,7-dihidro-tieno(2,3-b)piridina-5-carboxamidas como agentes antivirales.
NZ502988A (en) 5-Acetamido-4-amino-2-propionyloxy-6-isopropoxy-1-cyclohexene useful for treating influenza
EP0903347A4 (es)
EP1230925A4 (en) ANTI-HIV COMPOSITIONS
TR200402534T4 (tr) Viral enfeksiyonların tedavisinde yararlı oksazinokuinolonlar.
EP4644394A3 (en) Antiviral compounds
MY117789A (en) Pyrroloquinolones as antiviral agents
WO2001098275A3 (en) 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
PT828721E (pt) 2-amino-benxoxazinonas para o tratamento de infeccoes virais
PT1140113E (pt) Utilizacao de bisfosfonatos para profilaxia e tratamento de processos infecciosos
WO2001025239A3 (en) Oxazinoquinolones useful for the treatment of viral infections
EA200100711A1 (ru) Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция